EyePoint Inc (EYPT)

• Market cap: $1.02B
• 1 day: -6.91%
• 5 days: 5.66%
• 1 month: -1.78%
• 3 months: -9.81%
• 6 months: -26.04%
• Year to date: -30.61%
• 1 year: 36.29%
• 5 years: 27.55%
• 10 years: -62.79%
• Sector: Healthcare
• Industry: Biotechnology

About: EyePoint Inc focuses is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained-release product candidate for retinal diseases, with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.

Employees: 214